Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19
The sudden outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in Wuhan city, China, has resulted in a global pandemic, posing a major health concern worldwide. Despite multiple therapeutic interventions, no treatment has yet proven effective in treating COVID-19....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Current Medicine Research and Practice |
| Subjects: | |
| Online Access: | http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=3;spage=121;epage=124;aulast=Michelle |
| _version_ | 1811313838165852160 |
|---|---|
| author | I Jerlin Michelle S A Shevaani Kiran Kumar Rathinam Justin Jacob Abraham Muhasaparur Ganesan Rajanandh Thangavel Mahalingam Vijayakumar |
| author_facet | I Jerlin Michelle S A Shevaani Kiran Kumar Rathinam Justin Jacob Abraham Muhasaparur Ganesan Rajanandh Thangavel Mahalingam Vijayakumar |
| author_sort | I Jerlin Michelle |
| collection | DOAJ |
| description | The sudden outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in Wuhan city, China, has resulted in a global pandemic, posing a major health concern worldwide. Despite multiple therapeutic interventions, no treatment has yet proven effective in treating COVID-19. Furthermore, the complicated virology of SARS-CoV-2 makes the process of identifying effective treatments, an arduous task. COVID-19, being affecting the upper and lower respiratory tract, is associated with consequent release of pro-inflammatory cytokines in which interleukin (IL)-6 receptor plays a key role. The elevated inflammatory cytokines resulting in a cytokine storm play a major role in the pathology of COVID-19. Siltuximab has become a keen interest for researchers because it is a chimeric, human-murine, immunoglobulin G monoclonal antibody that binds and neutralises human IL-6 with high affinity and specificity. In this article, we tried to evaluate why siltuximab is not a suitable option for treating novel coronavirus from the clinical study evidence. |
| first_indexed | 2024-04-13T11:00:43Z |
| format | Article |
| id | doaj.art-218ee54c50d1400099b3d70011953c64 |
| institution | Directory Open Access Journal |
| issn | 2352-0817 2352-0825 |
| language | English |
| last_indexed | 2024-04-13T11:00:43Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Current Medicine Research and Practice |
| spelling | doaj.art-218ee54c50d1400099b3d70011953c642022-12-22T02:49:24ZengWolters Kluwer Medknow PublicationsCurrent Medicine Research and Practice2352-08172352-08252021-01-0111312112410.4103/cmrp.cmrp_28_20Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19I Jerlin MichelleS A ShevaaniKiran Kumar RathinamJustin Jacob AbrahamMuhasaparur Ganesan RajanandhThangavel Mahalingam VijayakumarThe sudden outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in Wuhan city, China, has resulted in a global pandemic, posing a major health concern worldwide. Despite multiple therapeutic interventions, no treatment has yet proven effective in treating COVID-19. Furthermore, the complicated virology of SARS-CoV-2 makes the process of identifying effective treatments, an arduous task. COVID-19, being affecting the upper and lower respiratory tract, is associated with consequent release of pro-inflammatory cytokines in which interleukin (IL)-6 receptor plays a key role. The elevated inflammatory cytokines resulting in a cytokine storm play a major role in the pathology of COVID-19. Siltuximab has become a keen interest for researchers because it is a chimeric, human-murine, immunoglobulin G monoclonal antibody that binds and neutralises human IL-6 with high affinity and specificity. In this article, we tried to evaluate why siltuximab is not a suitable option for treating novel coronavirus from the clinical study evidence.http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=3;spage=121;epage=124;aulast=Michellecovid-19cytokine release syndromeinterleukin-6monoclonal antibodysiltuximab |
| spellingShingle | I Jerlin Michelle S A Shevaani Kiran Kumar Rathinam Justin Jacob Abraham Muhasaparur Ganesan Rajanandh Thangavel Mahalingam Vijayakumar Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 Current Medicine Research and Practice covid-19 cytokine release syndrome interleukin-6 monoclonal antibody siltuximab |
| title | Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 |
| title_full | Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 |
| title_fullStr | Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 |
| title_full_unstemmed | Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 |
| title_short | Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19 |
| title_sort | siltuximab a monoclonal antibody against the interleukin 6 receptor is not an ideal option for management of covid 19 |
| topic | covid-19 cytokine release syndrome interleukin-6 monoclonal antibody siltuximab |
| url | http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=3;spage=121;epage=124;aulast=Michelle |
| work_keys_str_mv | AT ijerlinmichelle siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 AT sashevaani siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 AT kirankumarrathinam siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 AT justinjacobabraham siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 AT muhasaparurganesanrajanandh siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 AT thangavelmahalingamvijayakumar siltuximabamonoclonalantibodyagainsttheinterleukin6receptorisnotanidealoptionformanagementofcovid19 |